National Stroke Foundation

Proventil HFA Inhalation Aerosol

The following drug information is obtained from various newswires, published medical journal articles, and medical conference presentations.

Approval Status:

Approved June 1999

Specific Treatments:

Pulmonary/Respiratory Diseases

Therapeutic Areas

General Information

The approval of Proventil HFA (albuterol sulfate) Inhalation Aerosol covers a supplemental new drug application that provides for the following: lowering the age from 12 years to 4 years and older for the treatment or prevention of

  • bronchospasm with reversible obstructive airway disease
  • exercise-induced bronchospasm